Post-transplant cyclophosphamide in one-antigen mismatched unrelated donor transplantation versus haploidentical transplantation in acute myeloid leukemia: a study from the Acute Leukemia Working Party of the EBMT

Battipaglia, Giorgia; Galimard, Jacques-Emmanuel; Labopin, Myriam; Raiola, Anna Maria; Blaise, Didier; Ruggeri, Annalisa; Koc, Yener; Guelbas, Zafer; Vitek, Antonin; Sica, Simona; Diez-Martin, Jose Luiz; Castagna, Luca; Bruno, Benedetto; Rovira, Montserrat; Moiseev, Ivan; Martino, Massimo; Grillo, Giovanni; Araujo, Mercedes Colorado; Bulabois, Claude Eric; Nguyen, Stephanie; Socie, Gerard; Arat, Mutlu; Pavlu, Jiri; Tischer, Johanna; Martin, Hans; Corral, Lucia Lopez; Choi, Goda; Forcade, Edouard; McDonald, Andrew; Pane, Fabrizio; Bazarbachi, Ali; Ciceri, Fabio; Nagler, Arnon und Mohty, Mohamad (2022): Post-transplant cyclophosphamide in one-antigen mismatched unrelated donor transplantation versus haploidentical transplantation in acute myeloid leukemia: a study from the Acute Leukemia Working Party of the EBMT. In: Bone Marrow Transplantation, Bd. 57, Nr. 4: S. 562-571

Abstract

Whether to choose Haploidentical (Haplo) or one-antigen mismatched unrelated donor (1Ag-MMUD) hematopoietic cell transplantation (HCT) with post-transplant cyclophosphamide (PTCy) remains an unanswered question. We compared PTCy- Haplo-HCT to PTCy-1Ag-MMUD-HCT for acute myeloid leukemia (AML) in complete remission (three groups: 1Ag-MMUD using peripheral blood (1Ag-MMUD-PB;n = 155);Haplo using bone marrow (Haplo-BM;n = 647) or peripheral blood (Haplo-PB;n = 949)). Haplo-BM and Haplo-PB had a higher non-relapse mortality (NRM) compared to 1Ag-MMUD-PB (HR 2.28, 95% CI 1.23-4.24, p < 0.01;HR 2.65, 95% CI 1.46-4.81, p < 0.01, respectively). Haplo groups experienced a lower leukemia-free survival (LFS) compared to 1Ag-MMUD-PB (Haplo-BM: HR 1.51, 95% CI 1.06-2.14, p = 0.02;Haplo-PB: 1.47, 95% CI 1.05-2.05, p = 0.02);overall survival (OS) was also lower in Haplo-HCT (Haplo-BM: HR 1.50, 95% CI 1.02-2.21, p = 0.04;Haplo-PB: HR 1.51, 95% CI 1.05-2.19, p = 0.03). No differences were observed for graft-versus-host/relapse-free survival (GRFS) and relapse incidence (RI). Haplo-BM was associated with a lower risk of grade III-IV acute graft-versus-host disease (GVHD) (HR 0.44, 95% CI 0.24-0.81;p < 0.01), while no statistical differences were observed between groups for grade II-IV aGVHD and for cGVHD. Use of PTCy in 1Ag-MMUD-HCT is a valid alternative to consider when using alternative donors. Larger analysis of 1Ag-MMUD versus Haplo-HCT are warranted.

• Dokumententyp: Zeitschriftenartikel
• Fakultät: Medizin
• Themengebiete: 600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin und Gesundheit
• ISSN: 0268-3369
• Sprache: Englisch